Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
Epidural blood patch in a patient with multiple sclerosis: is it safe?
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Fatigue in multiple sclerosis - A brief review.
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Management of children with multiple sclerosis.
A qualitative exploration of the impact of a 12-week group exercise class for those moderately affected with multiple sclerosis.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial.
Influence of pregnancy on neuromyelitis optica spectrum disorder.
Evaluation of sexual function in women at two stages of multiple sclerosis.
Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Optic nerve disease and axon pathophysiology.
Pages
« first
‹ previous
…
153
154
155
156
157
158
159
160
161
…
next ›
last »